Latest News

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. Bertrand Tombal discussing a subgroup analysis of the phase 3 HERO study assessing geographical efficacy and safety of relugolix versus leuprolide among men with advanced prostate cancer. Androgen deprivation therapy is a cornerstone of prostate cancer […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. Nuria Romero-Laorden discussing the final results of PRORADIUM, a study assessing the role of serum biomarkers of bone metabolism in mCRPC patients treated with radium-223. Radium-223 is a life-prolonging alpha-emitter bone targeted therapy for mCRPC patients […]

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Niven Mehra presented an exploratory ad hoc biomarker analyses assessing non-DDR/HRR mutational landscape and associations with antitumor activity among patients treated with talazoparib for metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-1 trial (NCT03148795).

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Wassim Abida presented an analysis of the safety and efficacy of tazemetostat in combination with abiraterone and prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Fred Saad presented a secondary analysis of the change in patient reported pain among patients treated with rucaparib for metastatic castration resistant prostate cancer (mCRPC) in the TALAPRO-1 trial (NCT03148795). This trial enrolled men with progressive mCRPC and […]

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Morgans presented an observational study characterizing treatment patterns and subsequent second-line therapy in both cisplatin-eligible and ineligible patients with aUC. In the past few years, programmed death 1/ligand 1 inhibitors (PD-1/L1i) have become recommended for first-line (1L) therapy […]

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Bellmunt provided an updated analysis from the DANUBE trial, evaluating PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC). The DANUBE trial was an open-label, phase III trial including patients with previously untreated mUC. The […]

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Emeline Colomba presented results from the ODENZA trial comparing darolutamide and enzalutamide, with a focus on cognitive assessment. Each of these agents is a next-generation androgen receptor inhibitor. However, darolutamide does not significantly penetrate the blood-brain barrier, which may reduce […]

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Michiel Van der Heijden presented on the design of the SunRISe-1 trial (NCT04640623).

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Higano presented a real-world analysis of pain efficacy of radium-223 treatment among patients with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. Radium-223 is a first-in-class alpha emitter which, based on the ALSYMPCA trial, is approved for patients […]